

**INFORMATION DISCLOSURE CITATION**

Form PTO-1449 (Modified)  
(Use several sheets if necessary)

ATTY. DOCKET NO.  
ROCH-002

SERIAL NO.  
09/568,559

APPLICANT

Allard, et al.

FILING DATE  
05-09-00

GROUP  
1643

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
AA	5,872,209	02/16/1999				
AB	5,427,954	06/27/1995				

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
AC	WO 99/09000	02/25/1999					
AD	WO 98/55643	10/12/1998					
AE	WO 98/51665	11/19/1998					
AF	WO 97/18207	5/22/1997					


**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

AG	Arner et al. (1998). "Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase" <i>Osteoarthritis Cartilage</i> , Vol. 6(3): 214-228.
AH	Arner et al. (1999). "Generation and Characterization of Aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity" <i>J. Biol. Chem.</i> , Vol. 274(10): 6594-6601.
AI	Billington et al. (1998). "An aggrecan-degrading activity associated with chondrocyte membranes" <i>Biochem J.</i> , Vol. 336(Pt 1): 207-212.
AJ	Buttner et al. (1998). "Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the 'aggrecanase' and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan" <i>Biochem J.</i> , Vol. 333(Pt 1): 159-165.
AK	Hughes et al. (1998). "Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage" <i>J. Biol. Chem.</i> , Vol. 273(46): 30576-30582.
AL	Illic et al. (1998). "Characterization of aggrecan retained and lost from the extracellular matrix of articular cartilage. Involvement of carboxyl-terminal processing in the catabolism of aggrecan" <i>J. Biol. Chem.</i> , Vol. 273(28): 1751-17458.
AM	Vankemmelbeke et al. (1999). "Coincubation of bovine synovial or capsular tissue with cartilage generates a soluble 'Aggrecanase' activity" <i>Biochem. Biophys. Res. Commun.</i> , Vol. 255(3): 686-691.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>CERTIFICATE OF MAILING</b>			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Donna Macedo		
Signature		Date	7/21/2000
<b>INFORMATION DISCLOSURE STATEMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	ROCH-002
		First Named Inventor	Allard, et al.
		Application Number	09/568,559
		Filing Date	May 9, 2000
		Group Art Unit	1170
		Examiner Name	N/A
		Title	Human Aggrecanase and Nucleic Acid Compositions Encoding the Same

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: 7. 21. 00

By:   
Bret E. Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\Documents\ROCH\002\IDS - before 1st OA.doc

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name Donna Macedo

Signature

*D. Macedo*

Date

7/21/2000

**NON FEE  
TRANSMITTAL**

*Note: Effective October 1, 1998.  
Patent fees are subject to annual revision.*

Attorney Docket Number

ROCH-002

First Named Inventor

Allard, et al.

Application Number

09/568,559

Filing Date

May 9, 2000

Group Art Unit

1643

Examiner Name

N/A

Title

Human Aggrecanase and Nucleic Acid  
Compositions Encoding The Same

Enclosed are the following documents:

Information Disclosure Statement;

Form PTO-1449;

13 Documents;

Return receipt postcard.

**CLAIMS**

No. of claims as filed or after amendment		Most claims previously paid		Extra claims		Fee from below		Fee Due
Total claims	-	20	=		x		=	
Ind. claims	-	3	=		x		=	
Multiple Dependent claims					x		=	
Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description				
103	18	203	9	Claims in excess of 20				
102	78	202	39	Independent claims in excess of 3				
104	260	204	130	Multiple dependent claim				
109	78	209	39	Reissue independent claims over original patent				
110	18	210	9	Reissue claims in excess of and over original patent				

**SUBMITTED BY**

Complete (if applicable)

Typed or Printed Name Bret E. Field, BOZICEVIC, FIELD & FRANCIS LLP

Reg. Number

37,620

Signature

Date

7.21.00

Deposit Account

50-0815